Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

17.01.2023 | main topic

Anticonvulsive treatment in autoimmune encephalitis: a systematic literature review

verfasst von: MD, MHBA Judith N. Wagner

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Epileptic seizures are a common manifestation of autoimmune encephalitis (AIE). Immunosuppression (IT) is an efficient therapeutic approach, particularly in AIE associated with antibodies against extracellular structures. The role of antiseizure medication (ASM) is less clear. However, it may be beneficial in disease refractory to IT or in chronic post-AIE epilepsy.

Methods

We conducted a systematic review assessing the PubMed and Cochrane databases to identify all reports on patients with epileptic seizures due to AIE in whom ASM was used and report it according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. We included case series (minimum 3 eligible patients), retrospective and prospective observational studies, and randomized controlled trials. The main outcome assessed was therapeutic efficacy of ASM. Secondary outcomes comprise number, type, and adverse effects of ASM. Descriptive statistics were used. The level of evidence was assessed according to the Centre for Evidence-Based Medicine.

Results

We screened a total of 3371 studies and included 30 (7 prospective, 23 retrospective). The reports cover a total of 708 patients, the majority (72.5%) suffering from AIE with antibodies against extracellular structures. Type of AIE, seizure frequency, and number and type of ASM used were heterogenous. While most patients profited from IT and/or ASM, the effect of ASM could rarely be isolated. Nine studies report on patients who received ASM monotherapy or were on ASM for a relevant length of time before IT initiation or after IT failure. One study reports a significant association between seizure freedom and use of sodium channel inhibitors. However, levels of evidence were generally low.

Conclusion

Few robust data exist on the particular efficacy of ASM in autoimmune epileptic seizures. While these patients generally seem to respond less well to ASM or surgical interventions, sodium channel blockers may have an additional benefit compared to other substances. However, levels of evidence are low and early IT remains the mainstay of AIE therapy. Future trials should address optimal ASM selection and dosing in AIE.
Literatur
1.
Zurück zum Zitat Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840–51. CrossRef Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840–51. CrossRef
2.
Zurück zum Zitat Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol. 2017;30:345–53. CrossRef Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol. 2017;30:345–53. CrossRef
3.
Zurück zum Zitat Shen C‑H, Fang G‑L, Yang F, Cai M‑T, Zheng Y, Fang W, et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABAB R encephalitis. Ann Clin Transl Neurol. 2020;7:1392–9. CrossRef Shen C‑H, Fang G‑L, Yang F, Cai M‑T, Zheng Y, Fang W, et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABAB R encephalitis. Ann Clin Transl Neurol. 2020;7:1392–9. CrossRef
4.
Zurück zum Zitat Bien CG. Management of autoimmune encephalitis. Curr Opin Neurol. 2021;34:166–71. CrossRef Bien CG. Management of autoimmune encephalitis. Curr Opin Neurol. 2021;34:166–71. CrossRef
5.
Zurück zum Zitat Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141:348–56. CrossRef Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141:348–56. CrossRef
6.
Zurück zum Zitat Sulentic V, Petelin Gadze Z, Derke F, Santini M, Bazadona D, Nankovic S. The effect of delayed anti-NMDAR encephalitis recognition on disease outcome. J Neurovirol. 2018;24:638–41. CrossRef Sulentic V, Petelin Gadze Z, Derke F, Santini M, Bazadona D, Nankovic S. The effect of delayed anti-NMDAR encephalitis recognition on disease outcome. J Neurovirol. 2018;24:638–41. CrossRef
7.
Zurück zum Zitat Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87:313–23. CrossRef Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87:313–23. CrossRef
8.
Zurück zum Zitat Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e353. CrossRef Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e353. CrossRef
9.
Zurück zum Zitat Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72–6. CrossRef Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72–6. CrossRef
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. CrossRef
11.
Zurück zum Zitat Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305–10. CrossRef Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305–10. CrossRef
12.
Zurück zum Zitat Mäkelä K‑M, Hietaharju A, Brander A, Peltola J. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol. 2018;9:579. CrossRef Mäkelä K‑M, Hietaharju A, Brander A, Peltola J. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol. 2018;9:579. CrossRef
13.
Zurück zum Zitat O’Connor K, Waters P, Komorowski L, Zekeridou A, Guo C‑Y, Mgbachi VC, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6:e552. CrossRef O’Connor K, Waters P, Komorowski L, Zekeridou A, Guo C‑Y, Mgbachi VC, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6:e552. CrossRef
14.
Zurück zum Zitat Kurukumbi M, Dave RH, Castillo J, Shah T, Lau J. Rituximab for autoimmune encephalitis with epilepsy. Case Rep Neurol Med. 2020;2020:5843089. Kurukumbi M, Dave RH, Castillo J, Shah T, Lau J. Rituximab for autoimmune encephalitis with epilepsy. Case Rep Neurol Med. 2020;2020:5843089.
15.
Zurück zum Zitat von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135:134–41. CrossRef von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135:134–41. CrossRef
16.
Zurück zum Zitat Dubey D, Samudra N, Gupta P, Agostini M, Ding K, Van Ness PC, et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure. 2015;29:143–7. CrossRef Dubey D, Samudra N, Gupta P, Agostini M, Ding K, Van Ness PC, et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure. 2015;29:143–7. CrossRef
17.
Zurück zum Zitat Dubey D, Konikkara J, Modur PN, Agostini M, Gupta P, Shu F, et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disord. 2014;16:494–9. CrossRef Dubey D, Konikkara J, Modur PN, Agostini M, Gupta P, Shu F, et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disord. 2014;16:494–9. CrossRef
18.
Zurück zum Zitat Gozubatik-Celik G, Ozkara C, Ulusoy C, Gunduz A, Delil S, Yeni N, et al. Anti-neuronal autoantibodies in both drug responsive and resistant focal seizures with unknown cause. Epilepsy Res. 2017;135:131–6. CrossRef Gozubatik-Celik G, Ozkara C, Ulusoy C, Gunduz A, Delil S, Yeni N, et al. Anti-neuronal autoantibodies in both drug responsive and resistant focal seizures with unknown cause. Epilepsy Res. 2017;135:131–6. CrossRef
19.
Zurück zum Zitat Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57–63. CrossRef Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57–63. CrossRef
20.
Zurück zum Zitat von Podewils F, Suesse M, Geithner J, Gaida B, Wang ZI, Lange J, et al. Prevalence and outcome of late-onset seizures due to autoimmune etiology: A prospective observational population-based cohort study. Epilepsia. 2017;58:1542–50. CrossRef von Podewils F, Suesse M, Geithner J, Gaida B, Wang ZI, Lange J, et al. Prevalence and outcome of late-onset seizures due to autoimmune etiology: A prospective observational population-based cohort study. Epilepsia. 2017;58:1542–50. CrossRef
21.
Zurück zum Zitat Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016;18:34–43. CrossRef Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016;18:34–43. CrossRef
22.
Zurück zum Zitat Quek AML, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582–93. CrossRef Quek AML, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582–93. CrossRef
23.
Zurück zum Zitat Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151–62. CrossRef Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151–62. CrossRef
24.
Zurück zum Zitat Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101–5. CrossRef Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101–5. CrossRef
25.
Zurück zum Zitat Baumgartner T, Pitsch J, Olaciregui-Dague K, Hoppe C, Racz A, Rüber T, et al. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis. Epilepsia. 2022;63:e100–e5. CrossRef Baumgartner T, Pitsch J, Olaciregui-Dague K, Hoppe C, Racz A, Rüber T, et al. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis. Epilepsia. 2022;63:e100–e5. CrossRef
26.
Zurück zum Zitat Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000;55:1823–8. CrossRef Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000;55:1823–8. CrossRef
27.
Zurück zum Zitat Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, et al. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2020;91:1145–53. CrossRef Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, et al. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2020;91:1145–53. CrossRef
28.
Zurück zum Zitat Chengyu L, Weixiong S, Chao C, Songyan L, Lin S, Zhong Z, et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J Neuroimmunol. 2020;345:577289. CrossRef Chengyu L, Weixiong S, Chao C, Songyan L, Lin S, Zhong Z, et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J Neuroimmunol. 2020;345:577289. CrossRef
29.
Zurück zum Zitat Gofshteyn JS, Yeshokumar AK, Jette N, Thakur KT, Luche N, Yozawitz E, et al. Clinical and electrographic features of persistent seizures and status epilepticus associated with anti-NMDA receptor encephalitis (anti-NMDARE). Epileptic Disord. 2020;22:739–51. CrossRef Gofshteyn JS, Yeshokumar AK, Jette N, Thakur KT, Luche N, Yozawitz E, et al. Clinical and electrographic features of persistent seizures and status epilepticus associated with anti-NMDA receptor encephalitis (anti-NMDARE). Epileptic Disord. 2020;22:739–51. CrossRef
30.
Zurück zum Zitat Goudot M, Frismand S, Hopes L, Verger A, Joubert B, Honnorat J, et al. GAD65-Ab encephalitis and subtle focal status epilepticus. Epileptic Disord. 2019;21:437–42. Goudot M, Frismand S, Hopes L, Verger A, Joubert B, Honnorat J, et al. GAD65-Ab encephalitis and subtle focal status epilepticus. Epileptic Disord. 2019;21:437–42.
31.
Zurück zum Zitat Hansen N, Widman G, Witt J‑A, Wagner J, Becker AJ, Elger CE, et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy Behav. 2016;65:18–24. CrossRef Hansen N, Widman G, Witt J‑A, Wagner J, Becker AJ, Elger CE, et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy Behav. 2016;65:18–24. CrossRef
32.
Zurück zum Zitat Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226–32. CrossRef Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226–32. CrossRef
33.
Zurück zum Zitat Hou R, Wu J, He D, Yan Y, Li L. Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients: Three case reports. Medicine (Baltimore). 2019;98:e15726. CrossRef Hou R, Wu J, He D, Yan Y, Li L. Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients: Three case reports. Medicine (Baltimore). 2019;98:e15726. CrossRef
34.
Zurück zum Zitat Jacob S, Irani SR, Rajabally YA, Grubneac A, Walters RJ, Yazaki M, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry. 2008;79:202–4. CrossRef Jacob S, Irani SR, Rajabally YA, Grubneac A, Walters RJ, Yazaki M, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry. 2008;79:202–4. CrossRef
35.
Zurück zum Zitat Lilleker JB, Jones MS, Mohanraj R. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2013;22:776–9. CrossRef Lilleker JB, Jones MS, Mohanraj R. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2013;22:776–9. CrossRef
36.
Zurück zum Zitat Liu X, Guo K, Lin J, Gong X, Li A, Zhou D, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update. Epilepsia. 2022;63:1812–21. CrossRef Liu X, Guo K, Lin J, Gong X, Li A, Zhou D, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update. Epilepsia. 2022;63:1812–21. CrossRef
37.
Zurück zum Zitat Sabanathan S, Abdel-Mannan O, Mankad K, Siddiqui A, Das K, Carr L, et al. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. Ann Clin Transl Neurol. 2022;9:67–78. CrossRef Sabanathan S, Abdel-Mannan O, Mankad K, Siddiqui A, Das K, Carr L, et al. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. Ann Clin Transl Neurol. 2022;9:67–78. CrossRef
38.
Zurück zum Zitat Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav. 2019;12:100326. CrossRef Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav. 2019;12:100326. CrossRef
Metadaten
Titel
Anticonvulsive treatment in autoimmune encephalitis: a systematic literature review
verfasst von
MD, MHBA Judith N. Wagner
Publikationsdatum
17.01.2023
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00998-z